Recursion Pharmaceuticals reported Q1 2026 progress on its AI-driven drug discovery programs, highlighting its first clinical proof of concept and multiple upcoming trial readouts. The company has ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Performances in N.Y.C. Advertisement Supported by This newly discovered play by Wilder is part picaresque, part fable, featuring a Midwestern boy who dreams of working at a department store in the big ...

A new approach to leadership for the team at the top by Darrell Rigby, Sarah Elk and Steve Berez “Brian Johnson” is the chief executive of a major consumer-goods company that has been remarkably ...

Zaya1-8B is a huge shift in LLMs, and the results are impressive.

You’re likely familiar with executive titles like chief executive officer (CEO), chief financial officer (CFO) and chief operating officer (COO). But what about roles like chief experience officer or ...

Imperagen, a Manchester-based techbio company using AI and quantum physics to engineer better enzymes faster, has closed a £5 ...

Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company.

In The Lancet in 1971, Julian Tudor Hart gave medicine one of its most important insights: the availability of medical care ...

Hepatitis C is liver inflammation and damage caused by infection with the hepatitis C virus. Hep C can cause a mild illness that lasts a short time (acute) or a serious illness that can last the rest ...

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...